Parkinson's disease-related disorders in the impulsive-compulsive spectrum.
In Parkinson's disease (PD), there is increasing evidence for disorders in the impulsive-compulsive spectrum, related to the disease itself, to the pharmacological management of this disease or to both. These disorders comprise dopamine deficiency syndrome (with immediate reward seeking behaviour), dopamine dependency syndrome (with addictive behaviour), dopamine dysregulation syndrome (with both addictive behaviour and stereotyped behaviour) and impulse control disorders (such as pathological gambling, compulsive shopping, binge eating and hypersexuality). These disorders are especially seen in PD patients with young age of onset, higher doses of antiparkinsonian drugs, pre-existent or current depression, pre-existing recreational drug or alcohol use, and high novelty seeking personality traits.Dopamine is not only implicated in voluntary movement control but also plays a significant role in the brain's reward system and the modulation of behaviours. Therefore, most if not all drugnaïve PD patients will suffer dysphoria, leading to mild immediate reward seeking behaviour as a consequence of the striatal dopaminergic denervation. In some of these patients, during treatment, this may even lead to the intake of increasing quantities of levodopa, above those required to adequately treat motor parkinsonism, with all characteristics of a dopamine dependence syndrome. These patients may develop plastic changes in the striatal matrix leading to hyperkinesia, caused by extracellular striatal dopaminergic fluctuations due to pulsatile dopamine replacement therapy. As soon as these changes are also seen in the striatal striosomes, in the framework of a dopamine dysregulation syndrome, stereotyped behaviours (punding) may occur (supposedly due to dorsal versus ventral striatal overactivity). Finally, impulse control disorders are suggested as being pure adverse side-effects of dopamine replacement therapy. Obsessive-compulsive behaviour (caused by ventral to dorsal overactivity) so far has not been described in PD patients.Treatment of impulse control disorders is related to the underlying pathology. In the case of an intrinsic dopamine deficiency syndrome, treatment with dopamine replacement therapy, especially levodopa, will help. In the multifactorial (intrinsic and extrinsic) dopamine dependency and dysregulation syndromes, addictive behaviour might best be helped by psychosocial strategies, and punding by continuous dopaminergic receptor stimulation (or amantadine), hypothesized to reduce the plastic changes-induced hypersensitization. The extrinsic impulse control disorders might be best treated by reducing or replacing dopamine receptor agonists.
Wolters
Eric Ch
ECh
Dept. of Neurology, VU University Medical Center, Amsterdam, The Netherlands. E.Wolters@vumc.nl
van der Werf
Ysbrand D
YD
van den Heuvel
Odile A
OA
D000978:Antiparkinson Agents / Q000009:adverse effects; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000139:chemically induced / Q000503:physiopathology*; D004298:Dopamine / Q000378:metabolism; D005715:Gambling / Q000523:psychology; D006801:Humans; D007175:Impulsive Behavior / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*
D000978:Antiparkinson Agents; D004298:Dopamine
Mov Disord. 2007 Jun 15;22(8):1179-81
17230464
J Neural Transm (Vienna). 2004 Oct;111(10-11):1303-15
15480840
Curr Opin Neurol. 2007 Aug;20(4):484-92
17620886
J Clin Psychiatry. 1996;57 Suppl 8:3-6
8698678
Mov Disord. 2008 Feb 15;23(3):411-5
18067187
Mov Disord. 2004 Apr;19(4):397-405
15077237
Ann Neurol. 2006 May;59(5):733-4
16634013
Mov Disord. 2000 Jul;15(4):669-77
10928577
J Neuropsychiatry Clin Neurosci. 2003 Summer;15(3):371-4
12928516
Eur J Pharmacol. 2005 Dec 5;526(1-3):199-206
16256105
Arch Gen Psychiatry. 2005 Aug;62(8):922-33
16061770
Parkinsonism Relat Disord. 2005 May;11(3):139-45
15823477
Neurology. 2006 Oct 10;67(7):1254-7
16957130
J Neural Transm Suppl. 2006;(70):309-19
17017546
Parkinsonism Relat Disord. 2005 Mar;11(2):85-8
15734665
Mov Disord. 2000 Sep;15(5):869-72
11009192
Behav Brain Res. 2005 Feb 28;157(2):253-63
15639176
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
12498954
Synapse. 2002 Jan;43(1):1-11
11746728
Biol Psychiatry. 1994 Sep 1;36(5):350-1
7993965
Arch Neurol. 2007 Feb;64(2):212-6
17296836
J Neurol. 2000 Apr;247 Suppl 2:II103-9
10991655
Neuroscience. 2005;136(4):1049-71
16226842
Parkinsonism Relat Disord. 2005 Sep;11(6):381-6
16109498
Pract Neurol. 2007 Nov;7(6):397-9
18024780
Drug Alcohol Depend. 2004 Dec 7;76(3):305-10
15561481
Arch Neurol. 2003 Dec;60(12):1745-8
14676050
Arch Neurol. 2006 Jul;63(7):969-73
16831966
J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):423-8
10727476
Arch Neurol. 2005 Sep;62(9):1377-81
16009751
Mov Disord. 2007 Dec;22(16):2339-45
17914729
J Clin Psychopharmacol. 2007 Feb;27(1):107-8
17224732
J Neurol Neurosurg Psychiatry. 2001 Mar;70(3):394-6
11181867
J Neurol Sci. 2008 Mar 15;266(1-2):216-28
17804018
J Neurol Neurosurg Psychiatry. 1999 Oct;67(4):492-6
10486397
J Neurosci. 2004 Aug 25;24(34):7557-65
15329403
Parkinsonism Relat Disord. 2008;14(1):28-32
17702628
J Neurosci. 2000 Mar 15;20(6):2369-82
10704511
Parkinsonism Relat Disord. 2007 Dec;13(8):516-9
17544807
Mov Disord. 2008 Jan;23(1):75-80
17960796
Neurology. 2003 Feb 25;60(4):601-5
12601099
Stroke. 2007 Apr;38(4):1390-2
17332454
Brain Dev. 2003 Dec;25 Suppl 1:S3-S14
14980365
Mov Disord. 2008 Jan;23(1):129-30
17960816
Mov Disord. 2006 Dec;21(12):2214-7
17013916
Eur J Nucl Med. 1999 Feb;26(2):171-82
9933352
J Neuropsychiatry Clin Neurosci. 2001 Spring;13(2):222-8
11449029
Lancet Neurol. 2003 Oct;2(10):595-604
14505581
World Psychiatry. 2007 Feb;6(1):14-8
17342214
Brain. 2005 Jun;128(Pt 6):1314-22
15716302
J Clin Psychiatry. 1995;56 Suppl 4:3-6; discussion 53-5
7713863
J Neurol Sci. 2008 Mar 15;266(1-2):197-203
17854836
Mov Disord. 2002 Nov;17(6):1371-4
12465087
Ann Neurol. 2006 May;59(5):852-8
16557571
Curr Opin Neurol. 2004 Aug;17(4):393-8
15247533
Neurology. 2006 Jun 13;66(11):1750-2
16769956
Prog Brain Res. 1990;85:119-46
2094891
Am J Psychiatry. 2006 Oct;163(10):1806-12
17012693
Prog Brain Res. 1990;85:95-116; discussion 116-8
2094917
Nat Clin Pract Neurol. 2007 Dec;3(12):664-72
18046439